QUOTEThe rollout of the vaccine – called Nuvaxovid – by the US-based drugmaker Novavax has been repeatedly hampered by a series of lengthy delays including production issues. It is making its appearance in the battle against the virus about a year after the novel mRNA vaccines produced by Pfizer/BioNTech and Moderna, and the viral vector vaccines made by Oxford/AstraZeneca and Johnson & Johnson. While those four simulate a virus in the body, Nuvaxovid uses a more traditional type of technology. It has been found to have an efficacy of over 90% in preventing symptomatic infection with the Alpha variant, and is currently undergoing further tests to check its ability to protect against the Omicron variant. 10ieSiDI0dAThis post has been edited by ycs: Yesterday, 04:38 PM

Source: The Guardian December 21, 2021 14:39 UTC